Characterization of serum polyunsaturated fatty acid profile in patients with inflammatory bowel disease.

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Jingjing Jiang, Lu Chen, Rui Sun, Ting Yu, Shuyu Jiang, Hong Chen
{"title":"Characterization of serum polyunsaturated fatty acid profile in patients with inflammatory bowel disease.","authors":"Jingjing Jiang,&nbsp;Lu Chen,&nbsp;Rui Sun,&nbsp;Ting Yu,&nbsp;Shuyu Jiang,&nbsp;Hong Chen","doi":"10.1177/20406223231156826","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the digestive tract. The aetiology and pathogenesis of IBD are complex, which may lead to metabolic disorders. As a kind of metabolite, polyunsaturated fatty acid (PUFA) is closely related to IBD.</p><p><strong>Objectives: </strong>The aim of this study was to explore the correlation between the serum PUFAs and the pathogenesis of IBD.</p><p><strong>Design: </strong>The study is a hospital-based case-control study.</p><p><strong>Methods: </strong>The serum free PUFAs of all participants, including 104 patients with IBD and 101 normal controls, were detected by liquid chromatography-mass spectrometry (LC-MS).</p><p><strong>Results: </strong>Compared with the normal control, the levels of C18:2, α-C18:3 (ALA), ɤ-C18:3, C20:4 (AA), C20:5 (EPA), ω-3 C22:5, ω-6 C22:5 and C22:6 (DHA) PUFAs in patients with Crohn's disease (CD) were obviously decreased. However, in patients with ulcerative colitis (UC), the levels of AA, EPA, ω-3 C22:5, ω-6 C22:5 and DHA were downregulated. The concentrations of seven PUFAs were significantly downregulated in the active CD group. In addition, four PUFAs had comparatively higher levels in the remission UC group.</p><p><strong>Conclusion: </strong>The present study revealed substantial differences in the levels of serum fatty acids between normal controls and patients with IBD. In detail, patients with CD were deficient in PUFAs, including the essential fatty acids. Moreover, as the disease activity aggravated, some PUFAs decreased dramatically.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231156826"},"PeriodicalIF":3.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/de/10.1177_20406223231156826.PMC10052691.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223231156826","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the digestive tract. The aetiology and pathogenesis of IBD are complex, which may lead to metabolic disorders. As a kind of metabolite, polyunsaturated fatty acid (PUFA) is closely related to IBD.

Objectives: The aim of this study was to explore the correlation between the serum PUFAs and the pathogenesis of IBD.

Design: The study is a hospital-based case-control study.

Methods: The serum free PUFAs of all participants, including 104 patients with IBD and 101 normal controls, were detected by liquid chromatography-mass spectrometry (LC-MS).

Results: Compared with the normal control, the levels of C18:2, α-C18:3 (ALA), ɤ-C18:3, C20:4 (AA), C20:5 (EPA), ω-3 C22:5, ω-6 C22:5 and C22:6 (DHA) PUFAs in patients with Crohn's disease (CD) were obviously decreased. However, in patients with ulcerative colitis (UC), the levels of AA, EPA, ω-3 C22:5, ω-6 C22:5 and DHA were downregulated. The concentrations of seven PUFAs were significantly downregulated in the active CD group. In addition, four PUFAs had comparatively higher levels in the remission UC group.

Conclusion: The present study revealed substantial differences in the levels of serum fatty acids between normal controls and patients with IBD. In detail, patients with CD were deficient in PUFAs, including the essential fatty acids. Moreover, as the disease activity aggravated, some PUFAs decreased dramatically.

Abstract Image

Abstract Image

Abstract Image

炎症性肠病患者血清多不饱和脂肪酸谱特征
背景:炎症性肠病(IBD)是一种慢性消化道炎性疾病。IBD的病因和发病机制复杂,可能导致代谢紊乱。多不饱和脂肪酸(PUFA)作为一种代谢物与IBD密切相关。目的:探讨血清PUFAs与IBD发病机制的关系。设计:本研究是一项以医院为基础的病例对照研究。方法:采用液相色谱-质谱法(LC-MS)检测104例IBD患者和101例正常人的血清游离PUFAs。结果:克罗恩病(CD)患者血清中C18:2、α-C18:3 (ALA)、ω -C18:3、C20:4 (AA)、C20:5 (EPA)、ω-3 C22:5、ω-6 C22:5、C22:6 (DHA) PUFAs水平明显低于正常对照组。而在溃疡性结肠炎(UC)患者中,AA、EPA、ω-3 C22:5、ω-6 C22:5和DHA水平下调。活性CD组7种PUFAs浓度显著下调。此外,四种pufa在缓解性UC组中水平相对较高。结论:本研究揭示了正常对照组和IBD患者血清脂肪酸水平的显著差异。详细地说,乳糜泻患者缺乏PUFAs,包括必需脂肪酸。此外,随着疾病活动度的加重,一些PUFAs显著下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Chronic Disease
Therapeutic Advances in Chronic Disease Medicine-Medicine (miscellaneous)
CiteScore
6.20
自引率
0.00%
发文量
108
审稿时长
12 weeks
期刊介绍: Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信